Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Minocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | USP2 | O75604 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.68 |
| ▸ | GRK6 | P43250 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minocycline SCHEMBL5175145 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL5175147 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL3969889 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL10477625 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL10477623 | 1.00 | TDP1 (0.70) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2537 | 0.99 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL1446032 | 0.99 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2539 | 0.99 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL21524892 | 0.99 | TDP1 (0.69) | TDP1KDM4EMAPTUSP2HPGD | |
| Minocycline SCHEMBL2865953 | 0.99 | TDP1 (0.71) | TDP1KDM4EMAPTUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355643-A1 | SOLVENT DELIVERY SYSTEM FOR TOPICAL DELIVERY OF ACTIVE AGENTS | LEO PHARMA A/S (DK) | 2023-11-09 | — | — | US | disclosed |
| CN-115379824-A | Solvent delivery system for topical delivery of active agents | 生物制药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-107708665-B | Pharmaceutical tetracycline compositions for dermatological use | 贝尔生物制药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4017474-A1 | SOLVENT DELIVERY SYSTEM FOR TOPICAL DELIVERY OF ACTIVE AGENTS | Timber Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021035086-A1 | SOLVENT DELIVERY SYSTEM FOR TOPICAL DELIVERY OF ACTIVE AGENTS | Timber Pharmaceuticals, Inc. (US) | 2021-02-25 | — | — | WO | disclosed |
| US-10881672-B2 | Pharmaceutical tetracycline composition for dermatological use | BioPharmX, Inc. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3273940-B1 | PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE | BIOPHARMX INC (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200046739-A1 | PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE | BioPharmX, Inc, | 2020-02-13 | — | — | US | disclosed |
| WO-2019164984-A1 | TOPICAL COMPOSITIONS WITH STABLE SOLUBILIZED SELECTIVE RETINOIDS AND/OR TETRACYCLINE-CLASS ANTIBIOTICS | BioPharmX, Inc. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-10391108-B2 | Pharmaceutical tetracycline composition for dermatological use | BioPharmX, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
| CN-107708665-A | pharmaceutical tetracycline compositions for dermatological use | 贝尔生物制药有限公司 | 2018-02-16 | — | — | CN | disclosed |
| EP-3273940-A2 | PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE | BIOPHARMX, INC. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20160279152-A1 | PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE | LEO PHARMA A/S (DK) | 2016-09-29 | — | — | US | disclosed |
| WO-2016154232-A2 | PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE | BioPharmX, Inc. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2009052152-A2 | TIGECYCLINE AND METHODS OF PREPARING INTERMEDIATES | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099376-A1 | TIGECYCLINE AND METHODS OF PREPARING INTERMEDIATES | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| EP-0812315-A1 | PYRAZOLOTETRACYCLINES | BIOCHIMICA OPOS SPA (IT) | 1997-12-17 | — | — | EP | disclosed |
| WO-1996026926-A1 | PYRAZOLOTETRACYCLINES | BIOCHIMICA OPOS S.P.A. (IT) | 1996-09-06 | — | — | WO | disclosed |
| US-5202449-A | Crystallization from acidity solution | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1993-04-13 | — | — | US | disclosed |
| US-4918208-A | Process for producing 7-dimethylamino-6-demethyl-6-deoxytetracycline | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099376-A1 | TIGECYCLINE AND METHODS OF PREPARING INTERMEDIATES | NOS2, NOS1, TET1 | TDP1 1689/4885KDM4E 786/4885MAPT 4544/4885 |
| US-20230355643-A1 | SOLVENT DELIVERY SYSTEM FOR TOPICAL DELIVERY OF ACTIVE AGENTS | CUTA, LIPA, CERS2 | TDP1 1711/4885KDM4E 2906/4885MAPT 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.